Treatment of type 2 diabetes mellitus using the traditional Chinese medicine Jinlida as an add-on medication: A systematic review and meta-analysis of randomized controlled trials

Zhao, Xuemin; Liu, Linfei; Liu, Jing

doi:10.3389/fendo.2022.1018450

Cited by 7 publications

(4 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A systematic review and meta-analysis of randomized controlled trials (RCT) showed that Jinlida Granules statistically and clinically reduced fasting plasma glucose, 2 hours plasma glucose and HbA1c in patients with T2D [ 25 ]. Few recent systematic review and meta-analysis of another RCT showed that the addition of the TCM in the treatment of T2D has a statistically significant effect on reducing HbA1c in Chinese adult patients with T2D [ 26 , 27 ].…”

Section: Discussionmentioning

confidence: 99%

The role of traditional Chinese medicine on fracture surgery, hospitalization, and total mortality risks in diabetic patients with osteoporosis

Liu,

Chung,

Lin

et al. 2024

PLoS ONE

View full text Add to dashboard Cite

Background Studies have confirmed that osteoporosis has been considered as one of the complications of diabetes, and the health hazards to patients are more obvious. This study is mainly based on the Taiwan National Health Insurance Database (TNHID). Through the analysis of TNHID, it is shown that the combined treatment of traditional Chinese medicine (TCM) medicine in patients of diabetes with osteoporosis (T2DOP) with lower related risks. Methods According to the study design, 3131 patients selected from TNHID who received TCM treatment were matched by 1-fold propensity score according to gender, age, and inclusion date as the control group. Cox proportional hazards analyzes were performed to compare fracture surgery, hospitalization, and all-cause mortality during a mean follow-up from 2000 to 2015. Results A total of 1055/1469/715 subjects (16.85%/23.46%/11.42%) had fracture surgery/inpatient/all-cause mortality of which 433/624/318 (13.83%/19.93%/10.16%) were in the TCM group) and 622/845/397 (19.87%/26.99%/12.68%) in the control group. Cox proportional hazards regression analysis showed that subjects in the TCM group had lower rates of fracture surgery, inpatient and all-cause mortality (adjusted HR = 0.467; 95% CI = 0.225–0.680, P<0.001; adjusted HR = 0.556; 95% CI = 0.330–0.751, P<0.001; adjusted HR = 0.704; 95% CI = 0.476–0.923, P = 0.012). Kaplan-Meier analysis showed that the cumulative risk of fracture surgery, inpatient and all-cause mortality was significantly different between the case and control groups (all log-rank p<0.001). Conclusion This study provides longitudinal evidence through a cohort study of the value of integrated TCM for T2DOP. More research is needed to fully understand the clinical significance of these results.

show abstract

Section: Discussionmentioning

confidence: 99%

The role of traditional Chinese medicine on fracture surgery, hospitalization, and total mortality risks in diabetic patients with osteoporosis

Liu,

Chung,

Lin

et al. 2024

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…From the current evidence of the trials, both Jinlida and metformin reduced the level of blood glucose, and the curative effect of Jinlida add-on metformin was superior to metformin monotherapy ( 10 – 13 ). In terms of the standard-reaching rate of blood glucose, Jinlida add-on metformin has obvious advantages in comparison to metformin monotherapy.…”

Section: Discussionmentioning

confidence: 99%

“…Our results showed that glycosylated hemoglobin (HbA1c) was reduced more significantly in the Jinlida group ( 10 , 11 ). Furthermore, meta-analysis and systematic reviews of Jinlida granules showed significant reductions in fasting blood glucose (FBG), 2-h postprandial blood glucose (2hPG), and HbA1c ( 12 , 13 ). Animal experiments show that Jinlida granules could promote the thermogenesis of brown and beige adipocytes by enhancing the mitochondrial function and inhibiting the expression of miR-27a, thereby improving the metabolism of glucose and lipids ( 14 , 15 ).…”

Section: Introductionmentioning

confidence: 99%

Jinlida granules combined with metformin improved the standard-reaching rate of blood glucose and clinical symptoms of patients with type 2 diabetes: secondary analysis of a randomized controlled trial

et al. 2023

View full text Add to dashboard Cite

BackgroundPrevious studies found that Jinlida granules could significantly reduce blood glucose levels and enhance the low-glucose action of metformin. However, the role of Jinlida in the standard-reaching rate of blood glucose and improving clinical symptoms has yet to be studied. We aimed to elaborate on the efficacy of Jinlida in type 2 diabetes (T2D) patients who experience clinical symptoms based on secondary analysis of a randomized controlled trial.MethodsData were analyzed from a 12-week, randomized, placebo-controlled study of Jinlida. The standard-reaching rate of blood glucose, the symptom disappearance rate, the symptom improvement rate, the efficacy of single symptoms, and the total symptom score were evaluated. The correlation between HbA1c and the improvement of clinical symptoms was analyzed.ResultsFor 12 weeks straight, 192 T2D patients were randomly assigned to receive either Jinlida or a placebo. The treatment group showed statistically significant differences in the standard-reaching rate of HbA1c < 6.5% (p = 0.046) and 2hPG (< 10 mmol/L, 11.1 mmol/L) (p < 0.001), compared with the control group. The standard-reaching rate of HbA1c < 7% (p = 0.06) and FBG < 7.0 mmol/L (p = 0.079) were not significantly different between the treatment and control groups. Five symptoms exhibited a statistical difference in symptom disappearance rate (p < 0.05). All the symptoms exhibited a significant difference in symptom improvement rate (p < 0.05). The mean change in total symptom score from baseline to week 12 was −5.45 ± 3.98 in the treatment group and −2.38 ± 3.11 in the control group, with statistically significant differences (p < 0.001). No significant correlations were noted between symptom improvement and HbA1c after 12 weeks of continuous intervention with Jinlida granules or placebo.ConclusionJinlida granules can effectively improve the standard-reaching rate of blood glucose and clinical symptoms of T2D patients, including thirst, fatigue, increased eating with rapid hungering, polyuria, dry mouth, spontaneous sweating, night sweat, vexing heat in the chest, palms, and soles, and constipation. Jinlida granules can be used as an effective adjuvant treatment for T2D patients who experience those symptoms.

show abstract

“…TCPMs that have been reported to combine with anti-hyperglycemic drugs to treat T2DM include Jinlida granules, Yuquan pill, and Tianqi capsules, etc. One systematic review demonstrated that integrated Jinlida granule and metformin were found to significantly improve HbA1c in subjects exhibiting poor glucose control as compared to metformin alone (7). Another trial demonstrated that after 12 weeks of treatment Tianqi capsule combined with metformin decreased the level of HbA1c and blood lipid indicators, and promoted insulin secretion in T2DM as compared with metformin alone (8).…”

Section: Introductionmentioning

confidence: 99%

Efficacy and safety of traditional Chinese patent medicine in collaboration with anti-hyperglycemic drugs on type 2 diabetes: study protocol for a multicenter, prospective cohort study

Pang¹,

Feng²,

Su³

et al. 2023

Ann Palliat Med

View full text Add to dashboard Cite

Background: Traditional Chinese patent medicine (TCPM) has potential in the treatment of type 2 diabetes mellitus (T2DM). Some studies have reported TCPMs could effectively reduce blood glucose levels in diabetic patients. To enhance glycemic control, relieve uncomfortable symptoms and delay diabetic complications, integrative TCPM and anti-hyperglycemic drugs is essential. Here, we investigated the efficacy and safety of using TCPM according to syndrome differentiation in co-collaboration with antihyperglycemic drugs.Methods: Participants that met the diagnostic criteria of T2DM and traditional Chinese medicine (TCM) syndrome differentiation were included. This is a two-arm multicenter, prospective cohort study.Two hundred and six participants will be included, the cohorts were divided according to the treatment methods they choose. Both groups will propose a healthy lifestyle, the exposure group used TCPMs based on syndrome differentiation, while the control group do not use other therapies. Basic therapy of antihyperglycemic, lipid-lowering and anti-hypertensive treatment accompanied with both groups. The study duration will be 24 weeks, and being followed up for 2 years afterward. Telephone follow-up will be done every two weeks and participant follow-up will be done every four weeks during the intervention period.The primary outcome will be the changes in glycosylated hemoglobin, the secondary outcomes include the changes of blood glucose, blood pressure, blood lipids, body weight, body mass index, waist circumference, hip circumference, incidence of diabetic microvascular and macrovascular complications and improvement in TCM symptoms. T test, Wilcoxon rank sum test, chi-squared test, or Fisher exact test were regarded as the main statistical methods for comparing the outcome variables. Statistical tests will be two-sided, and significance will be assigned at P<0.05.Discussion: The design of the trial coincides with the real-world practice of TCM. We assume that participants with T2DM will be helped by TCPMs. If succeeded, this study will furnish evidence that TCPM in collaboration with anti-hyperglycemic drugs could improve glycolipid metabolism, relieve subjective symptoms and delay the incidence of diabetic complications.

show abstract

Treatment of type 2 diabetes mellitus using the traditional Chinese medicine Jinlida as an add-on medication: A systematic review and meta-analysis of randomized controlled trials

Cited by 7 publications

References 59 publications

The role of traditional Chinese medicine on fracture surgery, hospitalization, and total mortality risks in diabetic patients with osteoporosis

The role of traditional Chinese medicine on fracture surgery, hospitalization, and total mortality risks in diabetic patients with osteoporosis

Jinlida granules combined with metformin improved the standard-reaching rate of blood glucose and clinical symptoms of patients with type 2 diabetes: secondary analysis of a randomized controlled trial

Efficacy and safety of traditional Chinese patent medicine in collaboration with anti-hyperglycemic drugs on type 2 diabetes: study protocol for a multicenter, prospective cohort study

Contact Info

Product

Resources

About